AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
Dr. Ning Dong on Clinical Updates on Classification, Treatment, and Emerging Trials of T-Cell Lymphoma
By The Cancer News Team
Dr. Ning Dong reviews updated WHO classification, frontline and relapsed treatment strategies, prognostic modeling in advanced cutaneous T-cell lymphoma, and promising phase 2 trials including CD5 CAR T therapy.
Dr. Ning Dong on Clinical Updates on Classification, Treatment, and Emerging Trials of T-Cell Lymphoma
By The Cancer News Team
Dr. Ning Dong reviews updated WHO classification, frontline and relapsed treatment strategies, prognostic modeling in advanced cutaneous T-cell lymphoma, and promising phase 2 trials including CD5 CAR T therapy.
Dr. Ning Dong on Clinical Updates on Classification, Treatment, and Emerging Trials of T-Cell Lymphoma
By The Cancer News Team
Dr. Ning Dong reviews updated WHO classification, frontline and relapsed treatment strategies, prognostic modeling in advanced cutaneous T-cell lymphoma, and promising phase 2 trials including CD5 CAR T therapy.
Dr. Sioban B. Keel on Germline Cancer Predisposition in Myeloid Malignancies
By The Cancer News Team
Dr. Sioban B. Keel reviews germline cancer predisposition in myeloid malignancies, highlighting DDX41, donor selection, somatic mosaicism, and how inherited risk reshapes diagnosis, monitoring, and transplant decisions.
Dr. Sioban B. Keel on Germline Cancer Predisposition in Myeloid Malignancies
By The Cancer News Team
Dr. Sioban B. Keel reviews germline cancer predisposition in myeloid malignancies, highlighting DDX41, donor selection, somatic mosaicism, and how inherited risk reshapes diagnosis, monitoring, and transplant decisions.
Dr. Sioban B. Keel on Germline Cancer Predisposition in Myeloid Malignancies
By The Cancer News Team
Dr. Sioban B. Keel reviews germline cancer predisposition in myeloid malignancies, highlighting DDX41, donor selection, somatic mosaicism, and how inherited risk reshapes diagnosis, monitoring, and transplant decisions.
Dr. L. Christine Fang on Modern De-Escalation in Breast Cancer Radiation Therapy
By The Cancer News Team
Dr. L. Christine Fang reviews modern de-escalation strategies in breast cancer radiation therapy, including hypofractionation, partial breast irradiation, and radiation omission for selected patients.
Dr. L. Christine Fang on Modern De-Escalation in Breast Cancer Radiation Therapy
By The Cancer News Team
Dr. L. Christine Fang reviews modern de-escalation strategies in breast cancer radiation therapy, including hypofractionation, partial breast irradiation, and radiation omission for selected patients.
Dr. L. Christine Fang on Modern De-Escalation in Breast Cancer Radiation Therapy
By The Cancer News Team
Dr. L. Christine Fang reviews modern de-escalation strategies in breast cancer radiation therapy, including hypofractionation, partial breast irradiation, and radiation omission for selected patients.
Dr. Brie Chun on Who Really Needs More Adjuvant Therapy in Early-Stage Breast Cancer?
By The Cancer News Team
Dr. Brie Chun reviews long-term SOFT and TEXT trial data to clarify which premenopausal patients with early-stage hormone receptor–positive breast cancer benefit most from ovarian function suppression.
Dr. Brie Chun on Who Really Needs More Adjuvant Therapy in Early-Stage Breast Cancer?
By The Cancer News Team
Dr. Brie Chun reviews long-term SOFT and TEXT trial data to clarify which premenopausal patients with early-stage hormone receptor–positive breast cancer benefit most from ovarian function suppression.
Dr. Brie Chun on Who Really Needs More Adjuvant Therapy in Early-Stage Breast Cancer?
By The Cancer News Team
Dr. Brie Chun reviews long-term SOFT and TEXT trial data to clarify which premenopausal patients with early-stage hormone receptor–positive breast cancer benefit most from ovarian function suppression.
Dr. Emily N. Palmquist on De-escalation of Axillary Surgery in Early-Stage Breast Cancer
By The Cancer News Team
Dr. Emily N. Palmquist reviews evidence from SOUND, INSEMA, and BOOG trials on safely omitting sentinel lymph node biopsy in select patients with early-stage breast cancer.
Dr. Emily N. Palmquist on De-escalation of Axillary Surgery in Early-Stage Breast Cancer
By The Cancer News Team
Dr. Emily N. Palmquist reviews evidence from SOUND, INSEMA, and BOOG trials on safely omitting sentinel lymph node biopsy in select patients with early-stage breast cancer.
Dr. Emily N. Palmquist on De-escalation of Axillary Surgery in Early-Stage Breast Cancer
By The Cancer News Team
Dr. Emily N. Palmquist reviews evidence from SOUND, INSEMA, and BOOG trials on safely omitting sentinel lymph node biopsy in select patients with early-stage breast cancer.
Dr. Chaitra S. Ujjani on B-Cell Lymphoma: Bispecific Antibodies and CAR T-Cell Therapy Updates from ASH
By The Cancer News Team
Expert highlights from Dr. Chaitra S. Ujjani on bispecific antibodies and CAR T-cell therapy in B-cell lymphomas, featuring key efficacy, safety, and practice-changing updates from the 2025 ASH meeting.
Dr. Chaitra S. Ujjani on B-Cell Lymphoma: Bispecific Antibodies and CAR T-Cell Therapy Updates from ASH
By The Cancer News Team
Expert highlights from Dr. Chaitra S. Ujjani on bispecific antibodies and CAR T-cell therapy in B-cell lymphomas, featuring key efficacy, safety, and practice-changing updates from the 2025 ASH meeting.
Dr. Chaitra S. Ujjani on B-Cell Lymphoma: Bispecific Antibodies and CAR T-Cell Therapy Updates from ASH
By The Cancer News Team
Expert highlights from Dr. Chaitra S. Ujjani on bispecific antibodies and CAR T-cell therapy in B-cell lymphomas, featuring key efficacy, safety, and practice-changing updates from the 2025 ASH meeting.
Dr. Michael Snyder on Advances in Genomic Medicine: Multi-Omics Approaches to Cancer Research and AI Applications in Precision Health
By The Cancer News Team
Dr. Michael Snyder of Stanford Medicine discusses how multi-omics research and artificial intelligence are reshaping cancer biology, early detection, and precision health, using familial adenomatous polyposis as a model.
Dr. Michael Snyder on Advances in Genomic Medicine: Multi-Omics Approaches to Cancer Research and AI Applications in Precision Health
By The Cancer News Team
Dr. Michael Snyder of Stanford Medicine discusses how multi-omics research and artificial intelligence are reshaping cancer biology, early detection, and precision health, using familial adenomatous polyposis as a model.
Dr. Michael Snyder on Advances in Genomic Medicine: Multi-Omics Approaches to Cancer Research and AI Applications in Precision Health
By The Cancer News Team
Dr. Michael Snyder of Stanford Medicine discusses how multi-omics research and artificial intelligence are reshaping cancer biology, early detection, and precision health, using familial adenomatous polyposis as a model.
Stanford Medicine Clinicians Highlight How Radiologists, Surgeons, and Pathologists Can Advance Precision Oncology Treatment
By The Cancer News Team
Stanford Medicine experts discuss how radiology, surgery, and pathology inform precision oncology, highlighting imaging phenotypes, treatment response assessment, and opportunities for surgical de-escalation in breast cancer care.
Stanford Medicine Clinicians Highlight How Radiologists, Surgeons, and Pathologists Can Advance Precision Oncology Treatment
By The Cancer News Team
Stanford Medicine experts discuss how radiology, surgery, and pathology inform precision oncology, highlighting imaging phenotypes, treatment response assessment, and opportunities for surgical de-escalation in breast cancer care.
Stanford Medicine Clinicians Highlight How Radiologists, Surgeons, and Pathologists Can Advance Precision Oncology Treatment
By The Cancer News Team
Stanford Medicine experts discuss how radiology, surgery, and pathology inform precision oncology, highlighting imaging phenotypes, treatment response assessment, and opportunities for surgical de-escalation in breast cancer care.
Dr. Stephen B. Gruber on Germline Genetic Testing in Cancer Treatment
By The Cancer News Team
Dr. Stephen B. Gruber discusses how germline genetic testing shapes cancer therapy selection, reveals gaps in current guidelines, and presents INSPIRE study data supporting universal access to comprehensive genetic testing.
Dr. Stephen B. Gruber on Germline Genetic Testing in Cancer Treatment
By The Cancer News Team
Dr. Stephen B. Gruber discusses how germline genetic testing shapes cancer therapy selection, reveals gaps in current guidelines, and presents INSPIRE study data supporting universal access to comprehensive genetic testing.
Dr. Stephen B. Gruber on Germline Genetic Testing in Cancer Treatment
By The Cancer News Team
Dr. Stephen B. Gruber discusses how germline genetic testing shapes cancer therapy selection, reveals gaps in current guidelines, and presents INSPIRE study data supporting universal access to comprehensive genetic testing.
Attorney Henry T. Greely on Navigating Ethical Challenges in Precision Oncology
By The Cancer News Team
A multidisciplinary panel led by Stanford ethicist Henry T. Greely, JD, examines the ethical challenges of precision oncology, including informed consent, access disparities, privacy concerns, and real-world clinical decision-making.
Attorney Henry T. Greely on Navigating Ethical Challenges in Precision Oncology
By The Cancer News Team
A multidisciplinary panel led by Stanford ethicist Henry T. Greely, JD, examines the ethical challenges of precision oncology, including informed consent, access disparities, privacy concerns, and real-world clinical decision-making.
Attorney Henry T. Greely on Navigating Ethical Challenges in Precision Oncology
By The Cancer News Team
A multidisciplinary panel led by Stanford ethicist Henry T. Greely, JD, examines the ethical challenges of precision oncology, including informed consent, access disparities, privacy concerns, and real-world clinical decision-making.